Source: Frontiers in Pharmacology. Unidade: FOB
Subjects: RECEPTORES DE ANGIOTENSINA, RATOS, DOENÇAS PERIODONTAIS, HIPERTENSÃO, MICROTOMOGRAFIA, OSTEOCLASTO, OSSO E OSSOS
ABNT
BRITO, Victor Gustavo Balera et al. Corrigendum: Telmisartan prevents alveolar bone loss by decreasing the expression of osteoclasts markers in hypertensive rats with periodontal disease. Frontiers in Pharmacology, v. 11, 2021Tradução . . Disponível em: https://doi.org/10.3389/fphar.2020.635927. Acesso em: 28 ago. 2024.APA
Brito, V. G. B., Patrocinio, M. S., Sousa, M. C. L. de, Barreto, A. E. A., Frasnelli, S. C. T., Lara, V. S., et al. (2021). Corrigendum: Telmisartan prevents alveolar bone loss by decreasing the expression of osteoclasts markers in hypertensive rats with periodontal disease. Frontiers in Pharmacology, 11. doi:10.3389/fphar.2020.635927NLM
Brito VGB, Patrocinio MS, Sousa MCL de, Barreto AEA, Frasnelli SCT, Lara VS, Santos CF dos, Oliveira SHP de. Corrigendum: Telmisartan prevents alveolar bone loss by decreasing the expression of osteoclasts markers in hypertensive rats with periodontal disease [Internet]. Frontiers in Pharmacology. 2021 ; 11[citado 2024 ago. 28 ] Available from: https://doi.org/10.3389/fphar.2020.635927Vancouver
Brito VGB, Patrocinio MS, Sousa MCL de, Barreto AEA, Frasnelli SCT, Lara VS, Santos CF dos, Oliveira SHP de. Corrigendum: Telmisartan prevents alveolar bone loss by decreasing the expression of osteoclasts markers in hypertensive rats with periodontal disease [Internet]. Frontiers in Pharmacology. 2021 ; 11[citado 2024 ago. 28 ] Available from: https://doi.org/10.3389/fphar.2020.635927